Tag: liraglutide

1. The combination of liraglutide and lifestyle therapy was shown to significantly reduce body mass index (BMI) standard-deviation score compared to the placebo group. 2. The use of liraglutide as adjuvant therapy was shown to cause a higher frequency of gastrointestinal adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is a chronic...

1. The combination of liraglutide and lifestyle therapy was shown to significantly reduce body mass index (BMI) standard-deviation score compared to the placebo group. 2. The use of liraglutide as adjuvant therapy was shown to cause a higher frequency of gastrointestinal adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is...

1. In children with type 2 diabetes (T2DM) on metformin, those randomized to liraglutide had better glycemic control after 26 weeks compared to placebo treated patients. 2. Patients treated with liraglutide experienced more adverse events and gastrointestinal issues than placebo patients. Evidence Rating Level: 1 (Excellent)   Study Rundown: Incidence of both childhood...

1. In children with type 2 diabetes (T2DM) on metformin, those randomized to liraglutide had better glycemic control after 26 weeks compared to placebo treated patients. 2. Patients treated with liraglutide experienced more adverse events and gastrointestinal issues than placebo patients. Evidence Rating Level: 1 (Excellent)   Study Rundown: Incidence of both...

1. This double-blinded, randomized controlled study found that liraglutide, a GLP-1 agonist, did no better than placebo in influencing post-hospitalization clinical stability. 2. There was no significant benefit of the drug in a subgroup of patients with type 2 diabetes. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure is a leading...

1. Patients with type 2 diabetes who received liraglutide were observed to have a significantly lower incidence of the composite of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, versus patients who received placebo. 2. The rates of both all-cause mortality and nephropathy were significantly lower for patients who...

1. In this small randomized controlled trial, addition of glucagon-like peptide 1 receptor agonist, liraglutide, to patients with type-2 diabetes receiving high-dose insulin therapy was associated with improved glycated hemoglobin (HbA1c) levels, weight loss, and patient satisfaction at six months. 2. Liraglutide therapy was associated with more hypoglycemic events during...

1. The combination of insulin degludec and the GLP1 antagonist, liraglutide, lowered the HbA1c in patients with type II diabetes to a greater extent than up-titration of insulin glargine. 2. Degludec/liraglutide was also associated with less adverse effects, including frequency of hypoglycemic episodes, weight gain, self-reported physical functioning, and overall...

  Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves The aim of this study was to examine the prevalence of reduced leaflet motion in biopresthetic aortic valves and its association with strokes and transient ischemic attacks (TIAs), and the effect of anticoagulation on leaflet motion. A total of 187 patients were...

1. For overweight and obese patients, the addition of liraglutide once daily to a diet and exercise regimen resulted in increased weight loss and improved overall health. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is an epidemic currently sweeping across the nation and worldwide. It is well documented that for...